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The development of a new vascular bed from a pre-existing
vascular network is an essential requirement for tumour growth
and progression. This phenomenon is regulated by a complex
network of cytokines, enzymes and adhesion molecules (Blood
and Zetter, 1990) and recent studies have shown that lymphocytes
and macrophages, as well as malignant cells, represent an impor-
tant source of such angiogenic factors within the tumour micro-
environment (Leek et al, 1994). Tumour necrosis factor alpha
(TNF-a) is a cytokine produced by different kind of human cells
(monocytes, macrophages, etc) and in particular from some
tumour-associated macrophages (TAMs). Although some works
have reported the endogenous expression of TNF-a in the epithe-
lial component of tumours, such as ovarian carcinoma (Naylor et
al, 1993), the majority of studies have found TNF-a expression
confined to the tumour-infiltrating inflammatory cells in the
tumour stroma. Indeed, lymphocytes isolated from breast cancer
biopsies secrete TNF-a in vitro (Rubbert et al, 1991), and various
techniques have been used to visualize the production of TNF-a
mRNA (Miles et al, 1994), intracellular TNF-a protein (Pusztai et
al, 1994) and secreted TNF-a by TAMs in breast carcinoma
(Lewis and McGee, 1996). However, the multifaceted roles of this
cytokine within solid tumours are largely unknown. Growth
factors of the transforming growth factor beta family (TGF-b)
have been reported as multifunctional growth factors and are
synthesized by a wide variety of both normal and malignant cells
(Derynk et al, 1985). TGF-b has multiple actions (Fajardo et al,
1996) and, owing to its highly potent inhibition function on cell
growth (Ueki et al, 1992), many studies have evaluated the prog-
nostic significance of the expression of this factor, especially in
breast cancer (Murray et al, 1993; Auvinen et al, 1995), but only
limited and confusing data are available at the moment.
Our preliminary studies have underlined that the clinical behav-
iour of NSCLC is strongly influenced by the development of a
newly formed vascular bed (Fontanini et al, 1997) which seems to
be under the control of particular proliferation-related genes such
as bcl-2 (Fontanini et al, 1998). In this respect it would be very
interesting to analyse the pattern of TNF-a and TGF-b in this type
of cancer to understand better their role as prognostic indicators
and to verify the putative interactions with angiogenesis and with
its genetic regulators.
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Summary Recent in vivo and in vitro studies have demonstrated a wide spectrum of biologic activities of cytokines in the pathogenesis and
progression of malignancy. Tumour necrosis factor alpha (TNF-a) and transforming growth factor beta (TGF-b) have emerged as two of the
many host-derived mediators that seem to interfere with both antiproliferative and tumorigenic effects in malignant tumours including lung
cancer. However, their association with tumour prognosis or prognostic factors has not yet been completely clarified. In this study, we
assessed TNF-a and TGF-b mRNA expression by RT-PCR technique in 61 NSCLC samples, demonstrating the presence of TNF-a and
TGF-b mRNA in 55.74% and 45.9% of cases, respectively. We also evaluated the expression of the two distinct transmembrane TNF
receptors. TNFR-I and TNFR-II, with a PCR-positive signal in 70.49% and 65.57% of cases, respectively. In 49 of the 61 cases, we evaluated
the prognostic impact of the two growth-inhibiting factors using the Kaplan–Meier analysis. In the univariate analysis patients without nodal
metastatic involvement (P = 0.02), less advanced tumour stage (P = 0.02) or TNF-a and TGF-b positive cancers (P = 0.01 and P = 0.03)
showed a favourable prognosis in terms of overall survival. Since our previous studies demonstrated a significant association between
NSCLC behaviour, neoangiogenesis and bcl-2 expression, we investigated the putative relation between TNF-a and TGF-b on the one hand,
and vascular count (as a measure of tumour angiogenesis) and bcl-2 protein expression, on the other hand. Our results showed a significant
direct association between TNF-a and bcl-2 (P = 0.05) and an inverse association between TNF-a and microvessel count (P = 0.03).
Moreover, as previously demonstrated, we observed a significant inverse correlation between bcl-2 protein expression and vascular count
(P = 0.05), suggesting that the favourable effect of TNF-a on clinical outcome may be related to a bcl-2-mediated low neovascular
development. © 2000 Cancer Research Campaign
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MATERIALS AND METHODS
Surgical specimens
61 NSCLC patients who had undergone curative surgical resection
at the Department of Surgery, University of Pisa, between 1991
and 1997, were analysed. There were 47 males and 14 females
(mean age 62.9 years, median 64, range 42–77). The most
common histologic type was squamous carcinoma (25 cases)
followed by adenocarcinoma (17 cases), large cell anaplastic
carcinoma (4 cases) and bronchiolo-alveolar carcinoma (3 cases).
Tumour samples were in part frozen in liquid nitrogen and stored
at –80°C for molecular studies and in part formalin-fixed and
paraffin-embedded for histological and immunohistochemical
processing. Data on clinical behaviour were available in 49 of the
61 cases (median follow-up 77 months). Tumours were classified
according to the World Health Organization classification (1982)
and according to the guidelines of the American Joint Committee
for Cancer Staging (1992).
RNA extraction
Total RNA was extracted from frozen lung-tissue samples using
RNeasy Mini Kit (Quiagen, M-Medical srl, Florence, Italy); the
RNeasy procedure represents a novel technology which combines
the selective binding properties of a silica-gel-based membrane
with the speed of the microspin principle. Biological samples are
first lysed and homogenized in the presence of a highly denaturing
guanidinium isothiocyanate-containing buffer which immediately
inactivates RNases to ensure isolation of intact RNA. Ethanol is
added to provide appropriate binding conditions and the sample is
then applied to an RNeasy mini spin column where the total RNA
binds to the membrane and contaminants are efficiently washed
away. High-quality RNA is then eluted in 30 ml of water. Purified
RNA was digested with RNase-free DNase to guarantee that RNA
is completely free of DNA contamination.
RT-PCR analysis
A constant amount of total RNA (5 mg) was reverse-transcribed at
42°C for 60 min in a total 20 ml reaction volume using 1st-
strand™ cDNA Synthesis Kit (Clontech Laboratories Inc, Palo
Alto, CA, USA). cDNA was incubated at 95°C for 5 min to inacti-
vate the reverse transcriptase, and served as a template DNA for
amplification using the Gene Amp PCR System 2400 (Perkin-
Elmer Applied Biosystems, CA, USA). PCR was performed in a
standard 50 ml reaction mixture consisting of 10 mM Tris-HCl,
50 mM KCl, 1.5 mM MgCl2 (pH 8.3), 0.2 mM dNTPs, 50 pmoli
of each sense and antisense primer, and 2.5 U of Amplitaq DNA
Polymerase (EUROBIOTAQ ADN Polymerase, Les Ulis Cedex
B, France). Amplification was performed for 45 s at 94°C, 45 s at
60°C and 2 min at 72°C for 35 cycles. Lastly, an additional exten-
sion step was performed for 7 min. As negative control the DNA
template was omitted in the reaction.
PCR primers for TNF-a cDNA were as follows: forward
primer, 5¢-GAGTGACAAGCCTGTAGCCCATGTTGTAGCA-3¢;
reverse primer, 5¢-GCAATGATCCCAAAGTAGACCTGCCCA-
GACT-3¢ (Clontech Laboratories Inc). Amplified PCR products
were run on a 1.5% agarose gel containing 0.5 mg ml–1 ethidium
bromide and a single 444 bp band was detected. PCR primers for
TNFR-I cDNA were as follows: forward primer, 5¢-ATTTGCTG-
TACCAAGTGCCACAAAGGAACC-3¢; reverse primer, 5¢-GTC-
GATTCCCACAAACAATGGAGTAGAGC-3¢ (Clontech Labora-
tories Inc). PCR primers for TNFR-II cDNA were as follows:
forward primer, 5¢-GAATACTATGACCAGACAGCTCAGAT-
GTGC-3¢; reverse primer, 5¢-TATCCGTGGATGAAGTCGT-
GTTGGAGAACG-3¢ (Clontech Laboratories Inc). Amplified PCR
products were run on a 1.5% agarose gel containing 0.5 mg ml–1
ethidium bromide and a single 587 bp for TNFR-I and 403 bp for
TNFR-II band was detected. PCR primers for TGF-b cDNA were
as follows: forward primer, 5¢-GCCTCGGACACCAAC-
TATTGCT-3¢; reverse primer, 5¢-AGGCTCCAAATGTAGG-
GGCAGG-3¢ (Clontech Laboratories Inc). The presence of a PCR
band amplified with primer specific for GAPDH with the same
cDNAs was used as internal control. Amplified PCR products
were run on a 1.5% agarose gel containing 0.5 mg ml–1 ethidium
bromide and a single 161 bp band for TGF-b was detected. No
band was detected when no cDNA was added to PCR mixture.
The sequencing of the PCR products, carried out using the
cyclic kit (Perkin-Elmer) according to the manufacture’s recom-
mendation, has shown that we were observing the expected frag-
ments, in particular as concerns the fragment of TNF-a which is
located in the intron III between positions 404 and 847 and the
fragment of TGF-b which is located in the Intron IV between
positions 1678 and 1838 (data not shown).
Quantitative PCR reaction
In order to obtain the quantitation of TNF-a and TGF-b mRNA
levels we used a technique based on a competitive PCR approach
using non-homologous internal standard called PCR MIMICs
(Clontech). The method, already described by Boldrini et al
(1999), involves amplification of a heterologous DNA fragment
(BamHI/EcoRI 574 bp fragment of v-erbB) with a pair of
composite primers, which contain the target primer sequences
contiguous to a sequence that anneals the heterologous DNA frag-
ment. During amplification the target primer sequences were
incorporated into the products. Thus, we refer to this heterologous
competitor fragment as COMPETITOR because it competes with
the target gene for primer annealing and amplification. Known
amounts of this COMPETITOR (600 bp for TNF-a and 240 bp for
TGF-b) were added to aliquots of cDNA derived from 8 mg of
total RNA. The relative densitometric measure of the electro-
phoretic bands was then plotted and the point of equal intensity
between the bands of competitor PCR MIMIC and TSP was taken
as concentration of the cDNA sample.
Microvessel detection and counting
The method of microvessel detection and counting has been
described previously (Fontanini et al, 1997). Briefly, intratumour
microvessels were highlighted with anti-CD34 Mab (clone
QB-END 10, Novocastra, Newcastle, UK) which was diluted
1:100, overnight. Biotinylated anti-mouse IgG (Vector,
Burlingame, CA, USA) was applied for immunoreaction, followed
by detection using the ABC method. A single microvessel was
defined as any brown immunostained endothelial cell separated
from adjacent microvessels, tumour cells and other connective
tissue elements. Each sample was examined under low power (´10
objective lens and ´10 ocular lens) to identify the region of the
section with the highest number of microvessels. A ´250 field
(´25 objective lens and ´10 ocular lens; 0.74 mm2 per field) was482 L Boldrini et al
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counted in each area, and the count was recorded. Large vessels
with thick muscular walls were excluded in the counts. The lumen
was not required to identify a vessel.
Bcl-2 immunostaining
The 5 mm tumour sections were immunostained using the alkaline-
phosphatase-anti-alkaline phosphatase (APAAP) method (Cordell
et al, 1984) with the anti-bcl-2 monoclonal antibody (clone 124)
(Pezzella et al, 1992) raised to a synthetic peptide. Briefly, paraffin
sections were dewaxed in xylene and rehydrated through graded
alcohols. The monoclonal antibody bcl-2 124 was applied
overnight at 1:20 of dilution. A rabbit anti-mouse secondary anti-
body prediluted in 0.05 M Tris-buffered and containing normal
swine serum was applied for 30 min. The alkaline-phosphatase-
mouse anti-alkaline-phosphatase immune complex was applied for
30 min first and then for 10 min spaced by the use of the anti-
mouse serum. Reaction was developed with alkaline-phosphatase
substrate containing naphthol AS-MX, Fast-red Tr and Levamisol
(APAAP Kits, Dako Corporation). As positive control for bcl-2 we
used a paraffin-embedded section from a normal peribronchial
lymph-node removed during post-surgical sampling of a lung
tumour. At the same time, positive staining of small lymphocytes
provided internal control for bcl-2 staining. Staining without the
anti-bcl-2 monoclonal antibody was performed as negative control
procedure. The count of bcl-2 immunoreactivity was made by
scoring a minimum of five high-power fields (HPFs) (´40
objective lens).
Statistical analysis
All statistical analyses were carried out using STATISTICA soft-
ware (Stat-soft). Univariate analysis was performed by modeling
Kaplan–Meier survival curves. The Log-rank test was used to
evaluate the statistical significance of differences in survival
distributions among prognostic groups. Multivariate analysis was
carried out using the Cox proportional-hazard model.
Mann–Whitney and/or Kruskall–Wallis non-parametric tests
were used to compare clinico-pathological characteristics of the
tumours with median immunostaining values. The a priori level of
significance was set at P-value of less than 0.05.
RESULTS
TNF-a and TGF-b expression
TNF-a mRNA expression evaluated by PCR technique was
observed in 34 out of 61 cases (55.74%). TGF-b mRNA was
detected in 28 out of 61 cases (45.9%). Figure 1 (Upper panel)
shows the results of the electrophoretic analysis of PCR products
in representative cases. We have also quantified the expression of
the mRNA for both the cytokines using a competitive PCR
technique, as described in Materials and Methods. Figure 1 (lower
panel) shows the results of coamplification of COMPETITOR and
target-gene cDNA in representative cases.
TNF-receptors expression
The expression of the two distinct transmembrane TNF-receptors,
TNFR-I and TNFR-II, was also studied, with a PCR-positive
signal in 70.49% (43/61) and 65.57% (40/61) of cases,
respectively. An example of electrophoretic gel for PCR product of
TNFR-I and TNFR-II is shown in Figure 2.
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Figure 1 Upper panel: Electrophoretic analysis of PCR products for TNF-a and TGF-b on a 1.5% agarose gel containing 0.5 mg ml–1 ethidium bromide. A
single 444 bp band for TNF-a and a single 161 bp band for TGF-b were detected. Lane L: molecular weight markers (100 bp ladder, Pharmacia). Lanes 1–7:
seven different tumour samples. Lane 8: positive control. Lower panel: Electrophoretic analysis of competitive PCR products for TNF-a and TGF-b on a 1.5%
agarose gel containing 0.5 mg ml–1 ethidium bromide. The length of competitor was 600 bp for TNF-a and 240 bp for TGF-b. Lane L: molecular weight markers
(100 bp ladder, Pharmacia). Lane 2 (left) and 6 (right): amplification of competitor alone; lane 5: negative sample; lanes 1 (left) and 1–4 (right): coamplification of
competitor and target gene cDNAPrognostic evaluation of cytokines in NSCLC 483
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Association of TNF-a and TGF-b with
clinico-pathological characteristics and survival
We analysed the expression of TNF-a and TGF-b according to
different clinico-pathologic parameters, including histologic type,
but we did not find any significant statistical association.
Among the clinico-pathologic parameters analysed, the absence
of metastatic nodal involvement and early-staged tumours were
significantly associated with better overall survival (P = 0.02)
(Table 1). A similar statistically significant association was
observed between these characteristics and disease-free interval
(data not shown). At the univariate analysis TNF-a and TGF-b
were significantly associated with a favourable prognosis in terms
of overall survival (P = 0.01 and 0.03) (Table 1) (Figure 3, A and
B). Similar results were observed between TNF-a and TGF-b and
disease-free interval (data not shown). By multivariate analysis
nodal status, TNF-a and TGF-b expression retained an indepen-
dent level of significance (P = 0.02; P = 0.05; P = 0.05) (Table 2).
On the basis of the number of the cDNA molecules valuated with
competitive PCR for both TNF-a and TGF-b, we calculated the
median values for the two series of the samples (47 for TNF-a and
187 for TGF-b). In this way we distinguished tumours with low
from tumours with high expression of the two cytokines and we
performed survival analyses by the Kaplan–Meier method (Figure
3, C and D) confirming the prognostic value for both TNF-a and
TGF-b.
No correlation was observed between TNFR-I and TNFR-II
expression and survival.
TNF R I
587 bp
L1 2 3 4 5 6 7 8 L
TNF R II 
403 bp
L12345678L
Figure 2 Electrophoretic analysis of PCR products for TNFR-I (left panel) and TNFR-II (right panel) on a 1.5% agarose gel containing 0.5 mg ml–1 ethidium
bromide. A single 587 bp band for TNFR-I and a single 403 bp band for TNFR-II were detected. Lane L: molecular weight markers (100 bp ladder, Pharmacia).
Lanes 1–7: seven different tumour samples. Lane 8: positive control
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Figure 3 Overall survival according to (A) TNF-a mRNA expression and (B) TGF-b mRNA expression, in 49 patients with non-small lung cancer (o = alive
patients; x = dead patients). Overall survival curves obtained with competitive PCR for TNF-a mRNA expression (C) and TGF-b mRNA expression (D)484 L Boldrini et al
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Correlation with neoangiogenesis and bcl-2 expression
A significant direct association between TNF-a and  bcl-2 was
found (P = 0.05) (Table 3). Furthermore, TNF-a mRNA was
inversely associated with microvessel count. In fact, tumours with
a TNF-a mRNA positivity showed a significantly lower
microvessel density (≤ 20 microvessels) than tumours which did
not show TNF-a mRNA expression (P = 0.03) (Table 4).
Moreover, as previously demonstrated, we observed an inverse
significant correlation between bcl-2 protein expression and
vascular count (P = 0.04) (Table 5).
DISCUSSION
TNF-a expression
In this study we analysed the expression of two important
cytokines in a series of NSCLC in order to investigate their puta-
tive role in lung cancer behaviour and their relation with other
biological parameters which are likely to have an important
prognostic impact in this type of cancer (Pezzella et al, 1993;
Silvestrini et al, 1994; Fontanini et al, 1997; Koukourakis et al,
1997). In particular neoangiogenesis and bcl-2 protein expression
have shown to significantly affect NSCLC development and
progression, and in our previous studies we also underlined the
relationship between neoangiogenesis and bcl-2 protein (Fontanini
et al, 1998). The development of newly formed tumour micro-
vessels is regulated by a large network of interrelating factors
rather than one factor alone (Lewis and Balkwill, 1997).
In experimental systems, TNF-a can both inhibit and stimulate
angiogenesis in a dose-dependent manner, with high doses being
inhibitory, and low doses stimulatory (Fajardo et al, 1992; Leek et
al, 1994). In a number of immunohistochemical studies TNF-a has
appeared in particular in the cytoplasm of inflammatory cells and
tumour-associated macrophages (Pusztai et al, 1994), although a
proportion of neoplastic cells have shown to be TNF-a positive in
some human cancers such as breast (Leek et al, 1998) and lung
carcinomas (Tran et al, 1998). Substantially different results have
been obtained in these human models: in breast carcinoma a
significant association has been found between TNF-a and
thymidine phosphorylase expression, which is a factor known to
promote tumour angiogenesis (Fajardo et al, 1992; Fox et al,
1996); in lung cancer, where neoangiogenesis seems to play an
unfavourable prognostic role, TNF-a expression has shown to
produce a better clinical outcome (Tran et al, 1998). In contrast, an
antiproliferative effect of TNF-a has been demonstrated in various
malignancies such as prostate (Sherwood et al, 1990), colon
(Kemeny et al, 1990), (Heim et al, 1990), (Schiller et al, 1990),
kidney carcinomas (Skillings et al, 1992), as well as malignant
melanoma (Lienard et al, 1992). An antiproliferative effect of
TNF-a has also been found in lung cancer cell lines where an
Table 1 Univariate analysis
Patient and tumour Cases (n) Two-sided P
characteristics
Sex
Male 39 0.34
Female 10
Histology
Squamous 25 0.77
Nonsquamous 14
Tumour size
T1 10
T2 34 0.07
T3 5
Node status
N0 32
N1 4 0.02
N2 13
Stage
S1 31
S2 3 0.02
S3 15
TNF-a
Neg 21 0.01
Pos 28
TGF-b
Neg 21 0.03
Pos 28
Table 2 Cox’s proportional regression model of overall survival
Variables Beta St. Err. of tP
Beta
Gender 0.182 0.279 –0.654 NS
Age –0.461 0.453 –1.018 NS
Tumour status 0.452 0.296 1.527 NS
Node status 0.775 0.252 3.111 0.02
Stage –0.662 0.486 1.361 NS
TNF-a –1.519 0.554 –2.739 0.05
TGF-b –1.248 0.492 –2.535 0.05
Table 3 Relationship between TNF-a mRNA expression and bcl-2 protein
expression in 20 cases of non-small cell lung cancer
TNF-a
Pos Neg P
bcl-2 Pos 1 9 0.05
Neg 5 5
Table 4 Relationship between TNF-a mRNA expression and MVC in 46
cases of non-small cell lung cancer
TNF-a
Pos Neg P
MVC ≤20 17 6 0.03
>20 10 13
Table 5 Relationship between bcl-2 protein expression and MVC in 20
cases of non-small cell lung cancer
bcl-2
Pos Neg P
MVC ≤20 9 5 0.05
>20 1 5Prognostic evaluation of cytokines in NSCLC 485
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antitumorigenic function of TNF-a has been observed (Hong
et al, 1987; Munker et al, 1987; Yang et al, 1989). In vivo, Ohkura
et al (1990) have reported an inhibitory effect in vivo of a
combined TNF-a/IL1 treatment on pulmonary metastases in mice
affected by lung carcinoma. Diffuse macrophage clustering and
tumour hypoxia, frequently associated with lung cancer, may
increase the level of TNF-a and/or modify the expression of TNF-
a receptors, influencing the effect of this cytokine on tumour
angiogenesis.
In the current study, coexpression of TNF-a, TNFR-I and TNFR-
II in NSCLC has been found by RT-PCR assay, as also reported by
Tran et al (1998) who used an immunohistochemical technique. The
PCR method cannot discriminate between free TNF-a and receptor-
bound TNF-a, so that the positive signal we found in our cases can
either depend on TNF-a secreted by the tumour-infiltrating inflam-
matory cells, or result from autocrine production by the tumour
cells. Further analyses using immunocytochemistry will be
performed to localize TNF-a and their receptors, in order to clarify
the paracrine or autocrine effect of this cytokine in NSCLC. The
statistically significant association we found in our series of NSCLC
between TNF-a and favourable prognosis may be related to the
influence of TNF-a on tumour angiogenesis. In fact, tumours
expressing TNF-a showed a number of microvessels significantly
lower than tumours which did not express it.
Since our previous studies demonstrated a connection between
NSCLC behaviour, neoangiogenesis and bcl-2 expression, we
investigated the putative relation between TNF-a on the one hand,
and vascular count (as a measure of tumour angiogenesis) and bcl-
2 protein expression on the other. Our results show a significant
direct association between TNF-a and bcl-2; moreover, as previ-
ously demonstrated, we observed an inverse significant correlation
between bcl-2 protein expression and vascular count, suggesting
that the favorable effect of TNF-a on clinical outcome may be
related to a low bcl-2-mediated neo-vascular development. It has
been experimentally demonstrated that bcl-2-expressing cells
(Hennet et al, 1993) may survive to hypoxic alteration induced by
TNF-a in mouse fibrosarcoid cells.
This putative bcl-2-dependent resistance in NSCLC cells could
prevent necrosis and consequent hypoxic-induced angiogenic
growth factor up-regulation. Interesting data in this sense have
been reported in a series of NSCLC we previously analysed, which
showed a significant association between bcl-2 expression and low
levels of vascular endothelial growth factor. Hypoxic alterations
determined by high levels of TNF-a, induced by the large amount
of inflammatory cells frequently present in NSCLC, were able to
produce necrotic alterations in a great number of neoplastic cells
preserving bcl-2-expressing ones, with consequent reduced angio-
genesis and better prognosis.
TGF-b expression
The effects of TGF-b on tumour growth are controversial, so that
TGF-b is able to directly inhibit proliferation of epithelial cancer
cells (Lippman et al, 1987), but its immunosuppressive properties
can also promote tumour growth. TGF-b activity is generally
inhibitory to epithelial cells in vitro and has several effects on the
regulation of extracellular matrix components (Sporn et al, 1986).
Moreover, the cellular response to TGF-b and the presence of
several isoforms could be important factors for explaining the
conflicting results regarding its activity (Mizukami et al, 1990;
McCune et al, 1992; Walker et al, 1992).
In our study no correlation was found between TGF-b mRNA
expression and microvessels count, although samples with PCR-
positive signal for TGF-b tended to have a lower number of
vessels than the negative ones. However, we observed an inter-
esting association between TGF-b expression and survival, since
patients with TGF-b mRNA expression had a significantly better
prognosis than patients who did not express this cytokine. Similar
results were obtained also in breast carcinomas where the expres-
sion of TGF-b was associated with a longer disease-free interval
(Murray et al, 1993) and with absence of nodal metastatic involve-
ment. There is some evidence that the metastatic behaviour of a
tumour is strongly determined by its ability to break down the
basement membrane, possibly by the increased production of
collagenase (Liotta et al, 1991). Some endogenous proteinase
inhibitors may potentially inhibit this invasive process and the
TGF-b expression may protect against invasion by locally regu-
lating the basement membrane components from protease action.
These data can explain the association we found between TGF-
b mRNA levels and better prognosis in our series of NSCLC,
prompting us to further investigate the role of TGF-b as a prog-
nostic indicator or as a potential target for innovative therapies in
cancer.
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